Form 4: Progyny EVP Sells Shares Under Pre-Arranged 10b5-1 Plan

Progyny's EVP and General Counsel, Allison Swartz, reported the sale of common stock and shares withheld for taxes, both executed under a pre-arranged trading plan.

Summary

• Allison Swartz, Executive Vice President and General Counsel of Progyny, Inc., reported transactions involving the company's common stock on August 28, 2025.
• Sold 2,398 shares of common stock at a price of $22.96 per share.
• Disposed of 1,352 shares of common stock at a price of $23.02 per share, which were withheld for the payment of withholding taxes upon the vesting of restricted stock units.
• The sale of 2,398 shares was conducted pursuant to a Rule 10b5-1 trading plan, which was entered into on May 13, 2025.
• Following these reported transactions, Allison Swartz beneficially owns 78,345 shares of Progyny, Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan and included routine tax withholding makes it a non-event from a fundamental analysis perspective. It does not indicate a lack of confidence in the company.

Positives

• The sale of shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined transaction rather than an immediate reaction to market conditions.

Negatives

• An executive selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though it is a common practice for liquidity and diversification.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on past insider transactions.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing, which is a standard reporting document for insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information directly related to broader industry trends or competitive landscape within the fertility benefits management sector. Such transactions are common for executives managing personal finances and compensation.

Comparison to Industry Standards

• This filing reports standard insider transactions (stock sale under a 10b5-1 plan and tax withholding for RSU vesting). These types of transactions are common across all industries for executives of publicly traded companies and do not offer specific comparative insights into Progyny's performance against industry benchmarks or competitors like Carrot Fertility or Maven Clinic.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by an executive under a pre-arranged plan is unlikely to have a significant direct impact on existing shareholders, though some might interpret it as a minor negative signal.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (pre-planned sale and tax withholding) by an executive. It does not provide any new fundamental information about Progyny's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and look to broader company reports (e.g., 10-K, 10-Q) for investment decisions.

Keywords

Progyny, PGNY, Insider Trading, Form 4, Allison Swartz, Stock Sale, 10b5-1 Plan, Executive Compensation